Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Non-Current Liabilities: 2012-2025

Historic Total Non-Current Liabilities for Fennec Pharmaceuticals (FENC) over the last 7 years, with Sep 2025 value amounting to $43.9 million.

  • Fennec Pharmaceuticals' Total Non-Current Liabilities fell 22.45% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year decrease of 22.45%. This contributed to the annual value of $43.9 million for FY2024, which is 41.92% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Total Non-Current Liabilities is $43.9 million, which was up 0.03% from $43.9 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $56.8 million during Q2 2024, with a 5-year trough of $4.0 million in Q2 2022.
  • Over the past 3 years, Fennec Pharmaceuticals' median Total Non-Current Liabilities value was $43.9 million (recorded in 2025), while the average stood at $41.1 million.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Total Non-Current Liabilities soared by 536.24% in 2023, and later dropped by 22.63% in 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $5.0 million in 2021, then surged by 395.05% to $24.9 million in 2022, then rose by 24.23% to $30.9 million in 2023, then spiked by 41.92% to $43.9 million in 2024, then fell by 22.45% to $43.9 million in 2025.
  • Its last three reported values are $43.9 million in Q3 2025, $43.9 million for Q2 2025, and $43.9 million during Q1 2025.